Abstract. Lung fibroblasts are responsible for collagen secretion during normal tissue repair and the development of fibrosis. Many other prostaglandins have been reported to regulate collagen synthesis in lung fibroblasts, but the role of prostaglandin D 2 (PGD 2 ) is unknown. In this study, we investigated the effect of PGD 2 on type I collagen secretion in human lung fibroblasts. Pretreatment with PGD 2 (0.1 -10 μM, 1 h) significantly attenuated type I collagen secretion to the cell supernatant induced by transforming growth factor-β (TGF-β). Although an agonist on chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2) did not have any effect, the prostanoid DP-receptor agonist BW245C (0.01 -1 μM) suppressed TGF-β-induced collagen secretion. PGD 2 and BW245C significantly increased intracellular cAMP level. One-hour pretreatment with forskolin (0.1 -10 μM), dibutyryl-cAMP (0.01 -1 mM), and the protein kinase A (PKA)-activator N 6 -phenyl-cyclic AMP (100 μM) significantly reduced TGF-β-induced collagen secretion, while exchange protein activated by cAMP (Epac) activator 8-bromo-2′-Omethyladenosine-3′,5′-cyclic AMP (10 μM) did not affect collagen deposition. These results suggest that PGD 2 inhibits TGF-β-induced collagen secretion via intracellular cAMP accumulation through activating DP receptor.
Introduction
The lipid mediator prostaglandin D 2 (PGD 2 ) is one of the major products from arachidonic acid synthesized by cyclooxygenases (COXs). PGD 2 is mainly produced by activated mast cells or T cells in inflammatory conditions (1, 2) . The biological reactions of PGD 2 are mediated via two distinct G-protein coupled receptors, prostanoid DP receptor and/or chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2) (3) . PGD 2 is a critical factor in the pathogenesis of diseases including asthma and also involved in physiological events such as sleep and bone metabolism (4, 5) . In the lung, analysis of bronchoalveolar lavage fluid (BALF) demonstrated that PGD 2 is released in the airways following antigen challenge and plays a crucial role in allergic asthma and chronic obstructive pulmonary disease (6, 7) . In particular, PGD 2 causes bronchoconstriction and is able to elicit eosinophil infiltration in the airways (8) .
Fibroblasts are present in many tissues in the body and recognized as a critical cell type involved in tissue repair and development of fibrosis. Profibrogenic cytokines and growth factors activate fibroblasts to induce deposition of collagens and other extracellular matrix (ECM) components (9) . Among the mediators that influence ECM secretion, transforming growth factor-β (TGF-β) is a main factor of fibroblast activation (10) . TGF-β contributes not only to wound repair but also to the development of fibrosis in the lung, skin, and kidney (11) . Several studies have examined the role of prostaglandins in the activation of fibroblasts and the development of fibrosis in the lung. PGF 2α accelerates collagen secretion via TGF-β-independent manner, whereas PGE 2 inhibits collagen synthesis (12, 13) . However, the role of PGD 2 in collagen deposition in lung fibroblasts still remains unknown.
In this study, we assessed the effect of PGD 2 
Materials and Methods

Cell isolation and culture
Primary human fetal lung fibroblast IMR-90 cells (JCRB cell bank, Osaka) were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS). Cells between passage 4 and 11 were used for experiments. Cells were cultured in DMEM with reduced serum (1% FBS) for 48 h before all the experiments.
Measurement of collagen production
Collagen production was quantitated in cell culture supernatants by direct ELISA as described previously (14) . Briefly, 5 × 10 5 cells were cultured for 48 h in the serum-reduced medium described above plus 50 μg/ml ascorbic acid and 0.2 mM β-aminopropionitrile in order to promote collagen synthesis and prevent cross-linking. Cells were pretreated with various stimulants and inhibitors at each concentration for 1 h (details are given in the Results and figure legends) and then stimulated for another 48 h with 1 ng/ml TGF-β. Collagen in the supernatant samples was solubilized with 0.3 mg/ml pepsin under 0.15 M citric acid. Samples were then neutralized by adding 0.2 M Tris solution containing 0.15 M NaCl and kept at −80°C until measurement.
Samples and standards were diluted in carbonatebicarbonate buffer (pH 9.8) and coated directly on ELISA plates overnight at 4°C. After blocking with bovine serum albumin, polyclonal anti-collagen type I antibody (1:2,000) was added and incubated for 2 h at 37°C. For the secondary reaction, biotinylated anti-rabbit IgG (1:500) was added and incubated 1 h at 37°C. Final detection was performed by adding Alexa Fluor 680-conjugated streptavidin (1:500). The intensity was detected and quantified with the Odyssey system (LI-COR Biosciences, Lincoln, NE, USA). The result was expressed as a ratio of stimulated/unstimulated sample with the control ratio set at 1.0.
Measurement of intracellular cAMP production
To assess the intracellular production of cAMP, cells were treated for 15 min with the phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine (IBMX, 0.5 mM) before experiments. Then media was aspirated, cells were washed, and intracellular cAMP levels were determined by an ELISA kit (GE Healthcare, Milwaukee, WI, USA) according to the manufacturer's manual. Protein concentrations were determined by the Lowry method and cAMP levels were normalized to the amount of cell protein.
Materials
The chemical reagents used were as follows: polyclonal anti-collagen type I antibody (Abcam, Cambridge, UK); 8-bromo-2′-O-methyladenosine-3′,5′-cyclic AMP, N 6 -phenyl-cyclic AMP (BIOLOG Life Science Institute, Bremen, Germany); 13,14-dihydro-15-keto PGD 2 (DK-PGD 2 ); BWA868C, BW245C, PGD 2 , PGE 2 (Cayman Chemical, Ann Arbor, MI, USA); FBS (JRH Biosciences, Lenexa, KS, USA); Alexa Fluor 680-conjugated streptavidin (Life Technologies, Carlsbad, CA, USA); myristoylated protein kinase A (PKA) inhibitor 14-22 amide (Merck Millipore, Darmstadt, Germany); collagen type I, forskolin, IBMX (Sigma, St. Louis, MO, USA); biotinylated anti-rabbit IgG (Vector Laboratories, Burlingame, CA, USA); human recombinant TGF-β1 (Wako Pure Chemical Industries, Osaka); and dibutyryl cyclic AMP sodium salt (Yamasa Corporation, Chiba).
Statistical analyses
The results of the experiments are expressed as the mean ± S.E.M. Statistical evaluation of the data was performed by the paired or unpaired Student's t-test for comparison between two groups and by one-way analysis of variance followed by Dunnett's test for comparisons between more than two groups. Statistical significance was established at P-values lower than 0.05.
Results
PGD 2 and BW245C inhibit collagen secretion in lung fibroblasts
Type I collagen is the major collagen synthesized by activated fibroblasts in the repair process and the progress of fibrosis (15) . We first examined the effect of PGD 2 on type I collagen secretion in lung fibroblasts. As shown in Fig. 1A , 1 ng/ml TGF-β induced about 4-fold increase in type I collagen secretion (48 h after treatment, 4.12 ± 0.40; n = 4). Pretreatment with PGD 2 (0.1 -10 μM, 1 h) significantly inhibited the collagen secretion induced by TGF-β (TGF-β with 0.1 μM PGD 2 , 3.51 ± 0.25; with 1 μM PGD 2 , 3.32 ± 0.48; with 10 μM PGD 2 , 1.71 ± 0.30; n = 4). PGE 2 is known to be a potent inhibitor of collagen synthesis (13) . PGE 2 also attenuated collagen synthesis (TGF-β + 1 μM PGE 2 , 0.75 ± 0.27; n = 4).
To investigate which type of receptor was involved in the effect of PGD 2 , we applied synthetic agonists against prostanoid DP receptor and CRTH2. Although the CRTH2-selective agonist DK-PGD 2 did not inhibit collagen deposition, the prostanoid DP receptor-selec-tive agonist BW245C significantly inhibited collagen synthesis in fibroblasts in a dose-dependent manner 
BW245C induces intracellular cAMP elevation in lung fibroblasts
The prostanoid DP receptor couples to G s and then activates adenylate cyclase with an increase in intracellular cAMP. As shown in Fig. 2A , 15-min stimulation with PGD 2 (0.1 -10 μM) significantly increased intracellular cAMP levels in a dose-dependent manner (control, 34.6 ± 6.9 pmol/mg; 0.1 μM PGD 2 , 50.5 ± 10.9 pmol/mg; 1 μM PGD 2 , 59.7 ± 12.0 pmol/mg; 3 μM PGD 2 , 131 ± 45 pmol/mg; 10 μM PGD 2 , 167 ± 26 pmol/ mg; n = 4). BW245C (0.01 -1 μM) also increased intracellular cAMP (control, 30.6 ± 7.2 pmol/mg; 0.01 μM BW245C, 34.9 ± 5.2 pmol/mg; 0.1 μM BW245C, 57.5 ± 5.3 pmol/mg; 0.3 μM BW245C, 247 ± 80 pmol/mg; 1 μM BW245C, 391 ± 51 pmol/mg; n = 4). Forskolin (1 μM), an artificial adenylate cyclase activator, induced cAMP elevation to 743 ± 121 pmol/mg (n = 4). PGD2 and prostanoid DP-receptor agonist inhibits collagen secretion in lung fibroblasts. A) Human lung fibroblasts were treated for 48 h with 50 μg/ml ascorbic acid and 0.2 mM β-aminopropionitrile before the experiment. Cells were stimulated for another 48 h with 1 ng/ml TGF-β after pretreatment with 0.1 -10 μM PGD2 or with 1 μM PGE2 for 1 h. *P < 0.05, **P < 0.01, compared with TGF-β-treated cells. B) Fibroblasts were stimulated with 1 ng/ml TGF-β after pretreatment with 0.01 -1 μM BW245C or with 10 μM DK-PGD2 for 1 h. Cells were also stimulated with TGF-β and 10 μM PGD2 after pretreatment with 30 μM BWA868C for 1 h. *P < 0.05, **P < 0.01, compared with TGF-β-treated cells.
# P < 0.05, compared with TGF-β-treated cells pretreated with PGD2. 
Adenylate cyclase activation and cAMP elevation inhibit collagen secretion
We explored whether adenylate cyclase mediates downstream pathways of prostanoid DP-receptor agonism in lung fibroblasts. Cells were pretreated with forskolin for 1 h before TGF-β stimulation. As shown in Fig. 3A, forskolin (0.1 -10 μM) inhibited the TGF-β-induced collagen synthesis (1 ng/ml TGF-β alone, 4.57 ± 0.40; with 0.1 μM forskolin, 4.09 ± 1.17; with 1 μM forskolin, 1.66 ± 0.19; with 10 μM forskolin, 1.41 ± 0.17; n = 4). We next determined whether an exogenous cAMP stimulation inhibits lung fibroblast collagen deposition. One-hour pretreatment with dibutyryl-cAMP (db-cAMP, 0.01 -1 μM) showed an inhibitory effect against collagen deposition by TGF-β (1 ng/ml TGF-β alone, 4.72 ± 0.34; with 0.01 μM db-cAMP, 4.06 ± 0.31; 0.1 μM db-cAMP, 3.31 ± 0.79; 1 μM db-cAMP, 1.31 ± 0.14; n = 4, Fig. 3B ).
PKA activator attenuates collagen secretion
In lung fibroblasts, elevation of cAMP has been reported to activate both PKA and/or exchange protein activated by cAMP (Epac) (16) . To determine which cAMP effector is responsible for the inhibitory effect of BW245C, fibroblasts were pretreated for 1 h with a selective activator of either PKA or Epac. As shown in Fig. 4A , the PKA activator N 6 -Phenyl-cyclic AMP (PhecAMP, 100 and 300 μM) significantly reduced TGF-β-induced collagen secretion, while then Epac activator 8-bromo-2'-O-methyladenosine-3',5'-cyclic AMP (OMe-cAMP, 10 μM) did not (1 ng/ml TGF-β alone, 3.91 ± 0.48; with 100 μM Phe-cAMP, 1.65 ± 0.46; 300 μM Phe-cAMP, 0.75 ± 0.09; with 10 μM O-Me-cAMP, 4.09 ± 0.80; n = 4).
Finally, we examined whether the cAMP-PKA pathway mediates the anti-fibrotic effect of BW245C. As shown in Fig. 4B , 30-min pretreatment with the PKA inhibitor 14-22 amide (PKI, 10 μM) tended to abrogate the inhibitory effect of BW245C on collagen secretion, but its difference was not significant. (1 ng/ml TGF-β 
Discussion
Lung fibroblasts play a critical role in regulating extracellular matrix accumulation in the lung. Fibroblasts synthesize ECM components such as collagen I. Although ECM secretion from fibroblasts is important in wound healing following lung injury, excessive accumulation induced by TGF-β can lead to lung fibrosis. Revealing the effect of agents that attenuate collagen secretion provides a therapeutic approach for fibrosis in the lung.
Metabolites of arachidonic acid seem to have various roles in collagen secretion in lung fibroblasts. PGF 2α accelerates collagen secretion via prostanoid FP receptors and loss of prostanoid FP receptors attenuates pulmonary fibrosis in mice (12) . PGE 2 inhibits collagen synthesis via prostanoid EP2 receptors (13) . In this study, we demonstrated for the first time that PGD 2 inhibits TGF-β-induced collagen secretion. PGD 2 is generated mainly by mast cells, alveolar macrophages, and Th2 cells in the lung. The concentration of PGD 2 in BALF has been reported to be in the nanomolar range (17) . However, over 10-fold increase in BALF concentrations of PGD 2 was detected after endobronchial allergen instillation (18) . Therefore, the concentrations of PGD 2 in the present study are likely to be physiologically relevant in the lung.
We showed that the prostanoid DP-receptor agonist BW245C markedly reduces collagen secretion in lung fibroblasts. The expression of prostanoid DP receptor was already suggested in primary fibroblasts derived from human lung (19) . In tracheal fibroblasts and dendritic cells, stimulation of prostanoid DP receptors activates adenylate cyclase followed by the increase in intracellular cAMP (20) . In this study, treatment with PGD 2 and BW245C immediately increased intracellular cAMP level. Previous reports showed that other agents known to increase intracellular cAMP in lung fibroblasts, including β-agonists and PGE 2 , inhibit collagen synthesis (21, 22) . Together with our results, DP agonism may inhibit lung fibroblast activation through intracellular cAMP accumulation.
Increase in intracellular cAMP level can lead to several signaling pathways including PKA-and/or Epac-activation (23, 24) . In IMR-90, Epac inhibits cell proliferation but not collagen synthesis (16) . In rat cardiac fibroblasts, PKA and Epac both inhibit synthesis of collagen (25) , and adenosine receptor agonism reduces collagen synthesis through the cAMP-Epac pathway (26) . We here utilized IMR-90 and showed that a PKA analog mimicked the effect of PGD 2 and BW245C on collagen secretion, while an Epac analog did not. It seems that whether PKA and/or Epac is involved in cAMP signaling depends on species and tissues from which the fibroblasts are derived.
An interesting finding of this study is that PKAinhibition by PKI did not significantly reverse the inhibitory effect of BW245C on lung fibroblasts. It suggests that the anti-fibrotic effect of DP agonism is mediated at least partially through a novel signal mediator other than PKA. A previous study also showed that the Gs-coupled β 2 -adrenergic receptor agonist isoproterenol was able to up-regulate interleukin-6 expression in murine cardiac fibroblasts by a mechanism resistant to PKI (27) . Another group recently reported that PGD 2 can activate a transcription factor cAMP response element binding protein (CREB) via signaling through extracellular signal-regulated kinase (ERK) and p90 ribosomal S6 protein kinase 1 (RSK1) (28) . The cAMP-CREB cascade has been known to antagonize the anabolic effects of TGF-β on ECM deposition (29) . Thus these signal pathways might be involved in PGD 2 /DP-mediated anti-fibrotic responses.
In summary, we demonstrated that PGD 2 and the prostanoid DP-receptor agonist BW245C inhibits collagen secretion in lung fibroblasts. We also showed that cAMP accumulation mediates the inhibitory effect. Better understanding of the intracellular signal transduction that inhibits collagen secretion, especially prostanoid DP receptor-and cAMP-mediated pathways, may lead to the identification of novel potential targets for the treatment of aberrant accumulation of extracellular matrix and fibrosis in the lung.
